Part 3 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight

Lung Cancer – No Longer the Disease We Once Thought It Was

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a forward-looking episode of DoctoRx Unscripted, featuring leading thoracic oncologists Dr. Christine Lovly and Dr. Nate Pennell. Together, they examine innovations redefining what’s possible for patients with lung cancer: * Biomarker-driven therapy and molecular profiling; * Liquid biopsy and ctDNA testing; * AI-assisted detection and radiomics; and * Next-generation immunotherapies, including bispecifics, T-cell engagers, and personalized vaccines. They also share their perspectives on a critical challenge: translating scientific progress into real-world impact by expanding access and closing gaps in care. If you're working to advance oncology care—or interested in deepening your understanding of what’s shaping its future—this is a conversation you don’t want to miss.

Part 3 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight

Part 3 - The Movement Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.    In Part 3, Dr. Small sits down with patient advocate Lisa Salberg, founder of the Hypertrophic Cardiomyopathy Association (HCMA), to explore how a personal diagnosis evolved into a global movement—helping to establish more than 60 Centers of Excellence around the world.    The conversation reinforces why embedding the patient voice early is essential to advancing cardiovascular medicine.

Part 2 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight

Part 2 - The Shift Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.    In Part 2, Dr. Small welcomes HCM expert Dr. Matthew Martinez and leading cardiologist Dr. Nani Bhalla. Together, they examine why HCM has historically been so difficult to detect—and what has changed in recent years to begin altering that trajectory.    The discussion explores how earlier recognition, paired with more precise and individualized treatment decisions, can change outcomes in meaningful and lasting ways.

Part 1 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight

Part 1 - The Moment Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed.    In Part 1, NFL tight end Tommy Sweeney shares his experience being diagnosed with HCM. He reflects on his personal journey— from diagnosis and treatment decision making to his return to the NFL with his condition appropriately treated and well managed.    His story underscores a sobering reality: HCM can remain undetected even in individuals who receive frequent medical screenings, like elite athletes.

Part 2 - Myeloma: The New Playbook

Highlights include: • Early detection and the potential of screening studies like PROMISE and iStopMM • Modifiable risk factors—how diet, exercise, and inflammation shape disease and outcomes • Emerging therapies on the horizon • Why “down with dex” and other old beliefs deserve retirement • The personal “why” behind every advance in myeloma care About the Experts Dr. Paul Richardson Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews. Dr. Richardson is a paid consultant for BMS. Dr. Joseph Mikhael Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field. Dr. Mikhael was not compensated for his participation. Dr. Mecide Gharibo Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals. Dr. Gharibo is an employee of BMS.